Meriam Izon, MD
Endocrinology, Diabetes & Metabolism · Fort Collins, CONPI 1093723231
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $916 of the $1,476 with a category attached, or 62.0%. 8 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 53.6% of the total. Reporting peaked in 2019 at $699 and has fallen 79.4% since, to $144 in 2025.
Across 13 payments — averaging $113.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$791
- Insulet Corporation$237
- BETA Bionics, Inc.$144
- Mannkind Corporation$126
- Lilly USA, LLC$80
- Sanofi-aventis U.S. LLC$72
- plus $25 from 2 others
What the payments were for
- Travel & lodging$56138%
- Food & beverage$91662%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 5 | $791 |
| Insulet Corporation | 2 | $237 |
| BETA Bionics, Inc. | 1 | $144 |
| Mannkind Corporation | 1 | $126 |
| Lilly USA, LLC | 1 | $80 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Amgen | 1 | $13 |
| Cequr Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,476 in reported general payments places this provider in the 60th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 141 | $275,029 |
| JardianceEmpagliflozin | 212 | $274,094 |
| MounjaroTirzepatide | 128 | $168,976 |
| MycapssaOctreotide Acetate | 11 | $145,443 |
| TrulicityDulaglutide | 66 | $85,251 |
| JanuviaSitagliptin Phosphate | 42 | $54,847 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $53,703 |
| InvokanaCanagliflozin | 31 | $42,147 |
| Tresiba Flextouch U-100Insulin Degludec | 58 | $40,934 |
| Humalog Kwikpen U-100Insulin Lispro | 85 | $38,355 |
| Teriparatide | 13 | $34,691 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 26 | $33,826 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 34 | $32,492 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $32,277 |
| FarxigaDapagliflozin Propanediol | 25 | $29,958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $80 | $261,626227 claims |
| Sanofi-aventis U.S. LLCLantus | $72 | $4,92414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Fort Collins
- Polina KaloyanovaFort Collins$2K
- Alejandro MunozFort Collins$2K
- Barbara WidomFort Collins$2K
- Darin OlsonFort Collins$963
- Leigh PerreaultBoulder$1.7M
- Satish GargAurora$347K
- Viralkumar ShahAurora$256K
- Neda RasouliAurora$188K
- Michelle CassaraArvada$141K
- Halis AkturkAurora$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.